We support Investors, VCs, Banks and Boards with sector‑specific due diligence in Pharmaceuticals, Biotechnology, Healthcare and Aesthetics — combining Scientific, Regulatory, and Commercial lenses.
Our work spans asset Valuation, Risk/Gap Analysis, IP and Technology Audits, Capital Estimation, and Project Screening/Monitoring — delivering clear recommendations and action plans.
Comprehensive Due Diligence Scope
Evidence‑based assessments covering Science, Operations, Regulatory Posture, and Market Outlook.
- Asset & pipeline evaluation with Technical and Commercial Diligence.
- Risk/gap analysis across CMC, Clinical, Regulatory, and Quality systems.
- IP & Technology Platform Audits and FTO considerations.
- Capital estimates, operating models, and milestone roadmaps.
- Vendor/CDMO landscape checks and execution feasibility.
- Market sizing, competitive intelligence, and pricing/access review.
- Post‑investment monitoring and governance frameworks.
Technical & Regulatory Diligence
Assess CMC/clinical evidence, regulatory pathways, and quality maturity to de‑risk decisions.
Commercial & Financial Review
Model revenue scenarios, CapEx/OpEx, and go‑to‑market risks; validate pricing and access assumptions.
Execution & Governance
Define milestones, KPIs, vendor oversight, and risk registers for post‑investment tracking.
Our Approach
Independent, evidence‑driven reviews combining Scientific Audits with market and Financial Validation.
- Structured checklists across CMC, Clinical, Regulatory, Quality, and Commercial domains.
- Clear red/amber/green findings and prioritized actions.
Monitoring & Governance
Define KPIs, cadence, and reporting to track value creation post‑investment.
On-going Support
Dedicated consultancy, strategic advisory sessions, priority client support.
Investor Network & Expert Panels
We convene SMEs in CMC, cClinical, Regulatory, IP, and Market access to evaluate and accelerate opportunities.
Technology & IP
Platform assessments, IP positioning, and FTO risk awareness.
Market & Access
Market sizing, competitive mapping, pricing and reimbursement checks.
Financial Modeling
CapEx/OpEx, scenario analysis, and milestone‑based budgeting.
Frequently asked questions about Due Diligence
Scientific/Technical review, Regulatory pathways, Quality systems, Market/Financial Validation, and Risk Registers.
Yes — we assess platform maturity, differentiation, and potential FTO issues with expert input.
We build CapEx/OpEx models and milestone plans to inform valuation and governance.
Yes — we analyze demand drivers, competition, pricing, and access constraints in target regions.
We define KPIs, cadence, and reporting for technical, regulatory, and commercial progress; manage risks and course‑correct.